Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (vol 24, 16, 2024)

Şenocak Taşçı, ElifOyan, BaşakSönmez, ÖzlemMutlu, Arda UlaşAtçı, Muhammed MustafaSakin, AbdullahÖner, İremYeşil Çınkır, HavvaBozkurt, Mustafa2024-02-132024-02-132024Şenocak Taşçı, E., Oyan, B., Sönmez, Ö., Mutlu, A. U., Atçı, M. M., Sakin, A. ... Bozkurt, M. (2024). Comparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (vol 24, 16, 2024). BMC Cancer, 24(1). https://dx.doi.org/10.1186/s12885-024-11863-01471-2407https://dx.doi.org/10.1186/s12885-024-11863-0https://hdl.handle.net/20.500.12511/12264[Abstract Not Available]enAttribution 4.0 Internationalinfo:eu-repo/semantics/openAccessMetastatic Colorectal CancerChemotherapyRegorafenibThird-Line TreatmentComparing the efficacy of regorafenib and 5-fluorouracil-based rechallenge chemotherapy in the third-line treatment of metastatic colorectal cancer (vol 24, 16, 2024)Article24110.1186/s12885-024-11863-0Q200114830020000238262962